Last Action | 04/09/24: signed by Governor (Acts Ch. 155) |
---|---|
Title | AN ACT relating to addiction treatment. |
Bill Documents |
Acts Chapter 155
Current/Final Introduced |
Fiscal Impact Statements |
Actuarial Analysis
Local Mandate Additional Fiscal Impact Statements Exist |
Bill Request Number | 1792 |
Sponsor | R. Duvall |
Summary of Enacted Version | Amends KRS 205.536 to prohibit the Department for Medicaid Services or a Medicaid managed care organization from requiring or using certain utilization reviews for prescription drugs that contains an opioid antagonist; and amends KRS 304.17A-611 to prohibit insurers from requiring or using certain utilization reviews for prescriptions that contain an opioid antagonist, and to provide that the prohibition applies to health benefit plans issued or renewed after January 1, 2025. |
Summary of Original Version | Amend KRS 205.536 to prohibit the Department for Medicaid Services or a Medicaid managed care organization from requiring or using certain utilization reviews for prescription drugs that contain Naloxone; amend KRS 304.17A-611 to prohibit insurers from requiring or using certain utilization reviews for prescription drugs that contain Naloxone. |
Index Headings of Original Version |
Drugs and Medicines - Treatment of alcohol or opioid use disorder, Naloxone, utilization reviews, prohibition Insurance, Health - Treatment of alcohol or opioid use disorder, utilization review, Naloxone, prohibition Public Medical Assistance - Medicaid coverage, utilization review, Naloxone, prohibition State Agencies - Department for Medicaid Services, utilization review, Naloxone, prohibition State Agencies - Department of Insurance, utilization review, Naloxone, prohibition Medicaid - Department for Medicaid Services, utilization review, Naloxone, prohibition Alcoholism - Treatment, Naloxone, utilization reviews, prohibition Opioids - Treatment, Naloxone, utilization reviews, prohibition Actuarial Analysis - Treatment, Naloxone, utilization reviews, prohibition Local Mandate - Treatment of alcohol or opioid use disorder, utilization review, Naloxone, prohibition |
Jump to Proposed Amendments | House Committee Substitute 1 with Fiscal Impact Statements |
Votes | Vote History |
02/14/24 |
|
---|---|
02/23/24 |
|
02/29/24 |
|
03/01/24 |
|
03/05/24 |
|
03/06/24 |
|
03/07/24 |
|
03/13/24 |
|
03/21/24 |
|
03/22/24 |
|
03/25/24 |
|
03/26/24 |
|
03/27/24 |
|
03/28/24 |
|
04/09/24 |
|
Amendment | House Committee Substitute 1 |
---|---|
Fiscal Impact Statements |
Actuarial Analysis to House Committee Substitute 1
Local Mandate to House Committee Substitute 1 |
Summary | Retain original provisions, except replace "naloxone" with "an opioid antagonist"; provide Section 2 of the Act applies to health benefit plans issued or renewed after January 1, 2025; EFFECTIVE, in part, January 2025. |
Index Headings |
Drugs and Medicines - Treatment of alcohol or opioid use disorder, opioid antagonist, utilization reviews, prohibition Effective Dates, Delayed - Treatment, opioid antagonist, utilization reviews, prohibition, effective January 2025, in part Insurance, Health - Treatment of alcohol or opioid use disorder, utilization review, opioid antagonist, prohibition Public Medical Assistance - Medicaid coverage, utilization review, opioid antagonist, prohibition State Agencies - Department for Medicaid Services, utilization review, opioid antagonist, prohibition State Agencies - Department of Insurance, utilization review, opioid antagonist, prohibition Medicaid - Department for Medicaid Services, utilization review, opioid antagonist, prohibition Alcoholism - Treatment, opioid antagonist, utilization reviews, prohibition Opioids - Treatment, opioid antagonist, utilization reviews, prohibition |
Last updated: 9/26/2024 1:37 PM (EDT)